The estimated Net Worth of Sandford D Smith is at least $1.47 Milhão dollars as of 2 September 2022. Mr. Smith owns over 11,369 units of Cytokinetics Inc stock worth over $1,265,692 and over the last 13 years he sold CYTK stock worth over $0. In addition, he makes $199,654 as Independent Director at Cytokinetics Inc.
Sandford has made over 17 trades of the Cytokinetics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 11,369 units of CYTK stock worth $268,991 on 2 September 2022.
The largest trade he's ever made was exercising 29,032 units of Cytokinetics Inc stock on 19 November 2021 worth over $382,351. On average, Sandford trades about 2,913 units every 11 days since 2012. As of 2 September 2022 he still owns at least 23,539 units of Cytokinetics Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Sandford D. Smith is Independent Director of the Company. Mr. Smith has served as a member of our Board of Directors since March 2012. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation and President of Genzyme International. From 1986 to 1996, Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith has served on the Board of Directors of Akcea Therapeutics, Inc. since March 2017 and Neuralstem, Inc. since May 2014. He served on the Board of Directors of Arpicus Biosciences, Inc. from August 2014 to February 2019, Novelion Therapeutics Inc. from November 2016 to March 2017, Aegerion Pharmaceuticals, Inc. from January 2012 to March 2017 and NVenta Biopharmaceuticals Corporation from 2007 to 2009. Mr. Smith earned a B.S. from the University of Denver. Mr. Smith brings to our Board of Directors broad experience in matters relating to the launch and commercialization of new drugs in a wide range of therapeutic areas, and in particular drugs targeting rare disease indications. He also has extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries.
As the Independent Director of Cytokinetics Inc, the total compensation of Sandford Smith at Cytokinetics Inc is $199,654. There are 15 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.
Sandford Smith is 73, he's been the Independent Director of Cytokinetics Inc since 2012. There are 3 older and 17 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.
Sandford's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi..., ePartners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Cytokinetics Inc executives and other stock owners filed with the SEC include: